UBS analyst Dan Leonard lowered the firm’s price target on Fulgent Genetics (FLGT) to $20 from $27 and keeps a Neutral rating on the shares. The company reported a slight Q4 beat but guided 2025 lower, the analyst tells investors in a research note. The firm expects Fulgent’s growth to decelerate going forward given lower growth trends in its commodity oncology and pathology business.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FLGT:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue